Increase in Diagnosed Events and Revascularization Procedures Will Drive Market Growth in the Treatment of Acute Coronary Syndrome
Posted on: Monday, 1 August 2005, 09:00 CDT
WALTHAM, Mass., Aug. 1 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the growth of the markets for treatment of non- ST-elevation myocardial infarction (NSTEMI) and unstable angina, both of which are conditions of acute coronary syndrome, will be driven by an increase in the number of diagnosed events and revascularization procedures conducted to treat the indication.
"Key market drivers will include the increased use of Eli Lilly's ReoPro (abciximab) and The Medicines Company's Angiomax (bivalirudin) during percutaneous coronary interventions," said Ruth Brown, Ph.D., analyst at Decision Resources. "Angiomax has a short half-life, a favorable side-effect profile, and offers advantages over both unfractionated heparin and low- molecular-weight heparin in high-risk patients undergoing percutaneous coronary intervention. Another key driver is the increased use of Sanofi- Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) in all markets. Impressive clinical trial evidence now supports the use of dual antiplatelet therapy-aspirin plus clopidogrel-to treat acute coronary syndrome patients."
The new Pharmacor study, entitled Acute Coronary Syndrome: NSTEMI, also finds that the introduction of novel agents that address several unmet needs will also drive growth, although overall market value will be constrained by the patent expiries of popular agents from several key drug classes.
About Acute Coronary Syndrome
Coronary artery disease is the leading cause of death in the Western world. Unstable angina and non-ST-elevation myocardial infarction, both of which are conditions of acute coronary syndrome, are among the most frequent clinical manifestations of coronary artery disease.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010
- BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010
- Autonomy Gains Largest Market Share and Revenue Growth in Search and Discovery Market, According to Leading Market Research Firm
- Carnegie Communications Names New Executive Vice Presidents; Focuses on Providing Best Research, Marketing and Communications Solutions to Colleges & Universities
- Companies and Markets: Indian Food, Beverages and Tobacco Market Forecast to 2011 Market Report Available Now
- Key Statistics Telecom Market & Regulatory Overviews of the United Kingdom Market
- France - Key Statistics, Telecom Market & Regulatory Overviews Now Available
- IBEX Announces Release of New C2C Urine Assay for Arthritis Pharmaceutical Research Market
- New Age Media Systems Expands UK Facility to Develop Sales and Support of Marketing and Media Research Analysis Software
- HPSM going for more market share in PDA market, NEW STRAITS
 |
 |
User Comments (0)
RSS Feeds